Meanwhile, the 25-milligram dose of Novo Nordisk's oral semaglutide helped patients lose up to 16.6% of their weight on ...
Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most ...
MedPage Today on MSNOpinion
'Most Favored Nation' Pricing May Cut Drug Costs. It May Also Cut Off Rural America.
In November, the Trump administration resurrected a Most Favored Nation (MFN) reference pricing policy, which would tie drug ...
18hon MSN
Is Eli Lilly a Buy Before 2026?
Eli Lilly’s next-generation obesity treatment may prove highly effective for patients who have high BMI or suffer from ...
Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal ...
24/7 Wall St. on MSN
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Allstate, Chubb Ltd., Eli Lilly, KLA Corp., Lockheed Martin, MongoDB, Roku, and More
The futures are trading lower after what started as a bounce-back Monday turned into a reversal Monday, as the AI/Datacenter ...
Philadelphia has lagged in biotech R&D jobs despite University of Pennsylvania scientists playing a leading role in ...
Zacks Investment Research on MSN
Eli Lilly or Merck: Where should investors put their money?
Eli Lilly LLY and Merck MRK are both major global pharmaceutical companies with blockbuster drug portfolios and deep ...
The Brown County Community Foundation is pleased to announce the recipient of the 2026 Lilly Endowment Community Scholarship ...
A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...
Healio spoke with Matthew S. Davids, MD, about a recent study comparing continuous treatment with a Bruton tyrosine kinase inhibitor with time-limited venetoclax-based therapy for chronic lymphocytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback